JBM  Vol.5 No.4 , April 2017
Skin Delivery of Glucosamine and Chondroitin Sulphates—A Perspective on the Conservative Treatment for Osteoarthritis of the Knee
Abstract: Based upon a series of research studies, scientific organizations considered Glucosamine and Chondroitin “not appropriate” as osteoarthritis (OA) of the knee modifying drugs and uncertain as pain relievers. Research studies which served as foundation for the aforementioned conclusions focused on the oral use of the substances. On the other hand, studies recommend that topical administration in treating OA be considered first line therapy, since it is said to be advantageous for its efficacy in treating localized situations, as it allows greater local concentration and it results in smaller systemic effects. Studies found did not provide sufficient evidence for good development and application strategies and were not enough to prove the technique to be effective or non-effective. Several other aspects must be clarified. In order to enhance permeation and delivery of Glucosamine and Chondroitin to knee joint, combining the advantages of intravenous infusion therapy with the convenience of oral administration, the suggested course of action is to transform skin delivery technology, while clarifying other points discussed throughout this research study.
Cite this paper: Leite, C. , Coelho, J. , Muehlmann, L. , de Azevedo, R. and Sousa, M. (2017) Skin Delivery of Glucosamine and Chondroitin Sulphates—A Perspective on the Conservative Treatment for Osteoarthritis of the Knee. Journal of Biosciences and Medicines, 5, 11-20. doi: 10.4236/jbm.2017.54002.

[1]   Bhatia, D., Bejarano, T. and Novo, M. (2013) Current Interventions in the Management of Knee Osteoarthritis. Journal of Pharmacy and Bioallied Sciences, 5, 30-38.

[2]   Wilson, N., Sanchez-Riera, L., Morros, R., Diez-Perez, A., Javaid, M.K., Cooper, C., et al. (2015) Drug Utilization in Patients with Osteoosteo Arthritis: A Population- Based Study. Rheumatology, 54, 860-867.

[3]   Batool, F., Sohail, M., Ashraf, F., Rana, B., Mahmood, F. and Tanveer, S. (2015) Clinical Effectiveness of Glucosamine and Chondroitin Sulphate in Treatment of Osteoarthritis. International Journal of Pharmaceutical Sciences and Research, 6, 541-545.

[4]   Hochberg, M.C., Altman, R.D., April, K.T., Benkhalti, M., Benkhalti, M., Guyatt, G., et al. (2012) American College of Rheumatology 2012: Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research, 64, 465-474.

[5]   Jevsevar, D.S., Brown, G.A., Jones, D.L., Matzkin, E.G., Manner, P.A., Mooar, P., et al. (2013) The American Academy of Orthopedic Surgeons Evidence-Based Guideline on Treatment of Osteoarthritis of the Knee. Journal of Bone and Joint Surgery, 21, 571-576.

[6]   McAlindon, T.E., Bannuru, R.R., Sullivan, M.C., Arden, N.K., Berenbaum, F., Bierma-Zeinstra, S.M., et al. (2014) Osteoarthritis Research Society International Guidelines for the Non-Surgical Management of Knee Osteoarthritis. Osteoarthritis Cartilage, 22, 363-388.

[7]   Silva, J.A., Apolinário, A.C., Souza, M.S.R., Damasceno, B.P.G.L. and Medeiros, A.C.D. (2010) Cutaneous Administration of Drugs: Challenges and Strategies for the Development of Trans-dermal Formulations. Revista de Ciências Farmacêuticas Básica, 31, 125-131.

[8]   Jalón, E.G., Josa, M., Campanero, M.A., Santoyo, S. and Ygartua, P. (2000) Determination by High-Performance Liquid Chromatography of Ketoprofen in Vitro in Rat Skin Permeation Samples. Journal of Chromatography A, 870, 143-149.

[9]   Bortolon, F.F., Sato, M.E., Andreazza, R.C.S. and Bresolin, T.M.B. (2008) Effect of Enhancers on the in Vitro Percutaneous Absorption of Piroxicam from Compounding Formulations. Revista Brasileira de Farmácia, 44, 433-449.

[10]   Badran, M.M., Kuntsche, J. and Fahr, A. (2009) Skin Penetration Enhancement by a Microneedle Device in Vitro: Dependency on Needle Size and Applied Formulation. European Journal of Pharmaceutical Sciences, 36, 511-523.

[11]   Chorilli, M., Brizante, A.C., Rodrigues, C.A. and Salgado, H.R.N. (2007) General Aspects in Transdermal Systems of Drugs Release. Revista Brasileira de Farmácia, 88, 7-13.

[12]   Gill, H.S., Andrews, S.N., Sakthivel, S.K., Fedanov, A., William, I.R., Garber, D.A., et al. (2009) Selective Removal of Stratum Corneum by Microdermabrasion to Increase Skin Permeability. European Journal of Pharmaceutical Sciences, 38, 95-103.

[13]   Bruyère, O., Cooper, C., Pelletier, J.P., Branco, J., Brandi, L.M., Guillemin, F., et al. (2014) An Algorithm Recommendation for the Management of Knee Osteoarthritis in Europe and Internationally: A Report from a Task Force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 44, 253-263.

[14]   Hauselmann, H.J. (2001) Nutripharmaceuticals for Osteoarthritis. Best Practice and Research Clinical Rheumatology, 15, 595-607.

[15]   Velosa, A.P.P., Teodoro, W.R. and Yoshinari, N.H. (2003) Collagen in Osteoarthrotic Cartilage. Revista Brasileira de Reumatologia, 43,160-166.

[16]   Cohen, M., Wolfe, R., Mai, T. and Lewis, D. (2003) A Randomized, Double Blind, Placebo Controlled Trial of a Topical Cream Containing Glucosamine Sulfate, Chondroitin Sulfate, and Camphor for Osteoarthritis of the Knee. The Journal of Rheumatology, 30, 523-528.

[17]   Erhan, B., Gunduz, B., üstunel, S.H., Bardak, A.N., Feride, S., Gülsün, I. and Zuhal, K. (2012) The Efficacy of Topical Glucosamine Sulfate-Chondroitin Sulfate in Knee Osteoarthritis Treated With Physical Therapy: A Randomized, Double-Blind, Placebo-Controlled Study. Turkish Journal of Physical Medicine and Rehabilitation, 58, 194-198.

[18]   Hammad, Y.H., Hala, R.M. and Sobhy, M.M. (2015) Clinical and Biochemical Study of the Comparative Efficacy of Topical versus Oral Glucosamine/Chondroitin Sulfate on Osteoarthritis of the Knee. The Egyptian Rheumatologist, 37, 85-91.

[19]   Onigbinde, A.T., Talabi, A.E., Okulaja, I.A. and Dominic, O. (2011) Comparative Efficacy of Cycle-Ergometry Exercise and Glucosamine Sulphate Iontophoresis in Pain Management of Subjects with Sub-Acute Knee Osteoarthritis. Medicina Sportiva, 3, 1517-1521.

[20]   Onigbinde, A.T., Adesina, O.D., Tarimo, N. and Ojoawo, A. (2014) Comparative Effects of a Single Treatment Session Using Glucosamine Sulphate and Methyl Salicylate on Pain and Hamstring Flexibility of Patients with Knee Osteoarthritis. American Journal of Health Research, 2, 40-44.

[21]   Kielhorn, J., Melching-Kollmu, S. and Mangelsdorf, I. (2006) Environmental Health Criteria (EHC) 235: Dermal Absorption. World Health Organization, 102, 6-36.

[22]   Pellanda, C., Ottiker, E., Strub, C., Figueiredo, V., Rufli, T., Imanidis, G. and Surber, C. (2006) Topical Bioavailability of Triamcinolone Acetonide: Effect of Dose and Application Frequency. Archives of Dermatological, 298, 221-230.

[23]   Argoff, C.E. and Gloth, F.M. (2011) Topical Nonsteroidal Anti-Inflammatory Drugs for Management of Osteoarthritis in Long-Term Care Patients. Therapeutics and Clinical Risk Management, 7, 393-399.

[24]   Lee, C.W., et al. (2005) The Transdermal Profiles of Mediflex. Glucosamine Cream in Mouse and Man. National Congress of Indonesian Society of Rheumatology.

[25]   Zhao, Y., Moddaresi, M., Jones, S.A. and Brown, M.B. (2009) A Dynamic Topical Hydrofluoroal Kanefoam to Induce Nanoparticle Modification and Drug Release in Situ. European Journal of Pharmaceutics and Biopharmaceutics, 72, 521-528.

[26]   Morey, T.E., Modell, J.H., Shekhawat, D., Shah, D.O., Klatt, B., Thomas, G.P., et al. (2006) Anesthetic Properties of a Propofol Microemulsion in Dogs. Anesthesia & Analgesia, 103, 882-887.

[27]   Silva, J.A., Bedor, D.G.C., Damasceno, B.P.G.L., Oliveira, A.G., Egito, E.S.T. and Santana, D.P. (2009) Physicochemical Characterization and Development of a Microemulsion System for Transdermal Use. Journal of Dispersion Science and Technology, 31, 1-8.

[28]   Sioufi, A., Pommier, F., Boschet, F., Godbillon, J., Lavoignat, D. and Salliere, D. (1994) Percutaneous Absorption of Diclofenac in Healthy Volunteers after Single and Repeated Skin Delivery of Diclofenac Emulgel. Biopharmaceutics & Drug Disposition, 15, 441-449.

[29]   Thomas, B.J. and Finnin, B.C. (2004) The Transdermal Revolution. Drug Discovery Today, 9, 697-703.

[30]   Kaestli, L.Z, Wasilewski-Rasca, A.F., Bonnabry P. and Vogt-Ferrier, N. (2008) Use of Transdermal Drug Formulations in the Elderly. Drugs Aging, 25, 269-280.

[31]   Persiani, S., Roda, E., Rovati, L.C., Locatelli, M., Giacovelli, G. and Roda, A. (2005) Oral Bioavailability and Plasma Pharmacokinetics after Increasing Doses of Crystalline Glucosamine Sulfate in Man. Osteoarthritis Cartilage, 13, 1041-1049.

[32]   Persiani, S., Rotin, R., Trisolino, G., Rovati, L.C., Locatelli, M., Paganini, D., et al. (2007) Synovial and Plasma Glucosamine Concentrations in Osteoarthritic Patients Following Oral Crystalline Glucosamine Sulphate at Therapeutic Dose. Osteoarthritis Cartilage, 15, 764-772.

[33]   Kwoh, C.K., Roemer, F.W., Hannon, M.J., Moore, C.E., Jakicic, J.M., Guermazi, A., et al. (2014) Effect of Oral Glucosamine on Joint Structure in Individuals with Chronic Knee Pain. Arthritis & Rheumatology, 66, 930-939.

[34]   Messier, S.P., Mihalko, S., Loeser, R.F., Legault, C., Jolla, J., Pfruender, J., et al. (2007) Glucosamine/Chondroitin Combined with Exercise for the Treatment of Knee Osteoarthritis: A Preliminary Study. Osteoarthritis Cartilage, 15, 1256-1266.

[35]   Irsay, L., Borda, M.I., Nitu, A.D., Ciortea, V., Onac, I. and Ungur, R. (2010) Effectiveness of Glucosamine and Chondroitin Sulfate Combination in Patients with Primary Osteoarthritis. Applied Medical Informatics, 27, 47-54.

[36]   Clegg, D.O., Reda, D.J., Harris, C.L., Klein, M.A., O’Dell, J.R., Hooper, M.M., et al. (2006) Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. The New England Journal of Medicine, 354, 795-808.

[37]   Henrotin, Y. and Lambert, C. (2013) Chondroitin and Glucosamine in the Management of Osteoarthritis. Current Rheumatology Reports, 15, 1-9.